2026-04-13T08:25:31Zhttps://recercat.cat/oai/request

oai:recercat.cat:11351/92152025-10-24T07:46:58Zcom_2072_451667com_2072_378040col_2072_451668

2025-10-24T07:46:58Z urn:hdl:11351/9215 Integrated Management of Multiple Sclerosis Spasticity and Associated Symptoms Using the Spasticity-Plus Syndrome Concept: Results of a Structured Specialists’ Discussion Using the Workmat® Methodology Fernández, Oscar Martínez-Ginés, Maria Luisa Montero-Escribano, Paloma Prieto, Jose Maria Costa-Frossard França, Lucienne Ramió-Torrentà, Lluís Esclerosi múltiple Espasticitat muscular Cannabinoides DISEASES::Immune System Diseases::Autoimmune Diseases::Autoimmune Diseases of the Nervous System::Demyelinating Autoimmune Diseases, CNS::Multiple Sclerosis DISEASES::Pathological Conditions, Signs and Symptoms::Signs and Symptoms::Neurologic Manifestations::Neuromuscular Manifestations::Muscle Hypertonia::Muscle Spasticity CHEMICALS AND DRUGS::Organic Chemicals::Hydrocarbons::Terpenes::Cannabinoids::Cannabidiol ENFERMEDADES::enfermedades del sistema nervioso::enfermedades autoinmunitarias del sistema nervioso::enfermedades autoinmunes desmielinizantes del SNC::esclerosis múltiple ENFERMEDADES::enfermedades musculoesqueléticas::enfermedades musculares::espasticidad muscular COMPUESTOS QUÍMICOS Y DROGAS::compuestos orgánicos::hidrocarburos::terpenos::cannabinoides::cannabidiol Esclerosi múltiple; Espasticitat; Cannabinoides Múltiple esclerosis; Espasticidad; Cannabidiol Multiple sclerosis; Muscle spasticity; Cannabidiol Background: Multiple sclerosis (MS) treatment has radically improved over the last years; however, MS symptom management is still challenging. The novel Spasticity-Plus syndrome was conceptualized to frame several spasticity-related symptoms that can be addressed together with broad-spectrum medication, such as certain cannabinoid-based drugs. The aim of this project was to gain insight into Spanish neurologists' clinical experience on MS spasticity and associated symptoms, and to assess the acknowledgment and applicability of the Spasticity-Plus syndrome concept in patients with MS. Methods: Ten online meetings were conducted using the Workmat® methodology to allow structured discussions. Fifty-five Spanish neurologists, experts in MS management, completed and discussed a set of predefined exercises comprising MS symptom assessment and its management in clinical practice, MS symptoms clustering in clinical practice, and their perception of the Spasticity-Plus syndrome concept. This document presents the quantitative and qualitative results of these discussions. Results: The specialists considered that polytherapy is a common concern in MS and that simplifying the management of MS spasticity and associated manifestations could be useful. They generally agreed that MS spasticity should be diagnosed before moderate or severe forms appear. According to the neurologists' clinical experience, symptoms commonly associated with MS spasticity included spasms/cramps (100% of the specialists), pain (85%), bladder dysfunction (62%), bowel dysfunction (42%), sleep disorders (42%), and sexual dysfunction (40%). The multiple correspondence analysis revealed two main symptom clusters: spasticity-spasms/cramps-pain, and ataxia-instability-vertigo. Twelve out of 16 symptoms (75%) were scored >7 in a 0-10 QoL impact scale by the specialists, representing a moderate-high impact. The MS specialists considered that pain, spasticity, spasms/cramps, bladder dysfunction, and depression should be a treatment priority given their frequency and chance of therapeutic success. The neurologists agreed on the usefulness of the new Spasticity-Plus syndrome concept to manage spasticity and associated symptoms together, and their experience with treatments targeting the cannabinoid system was satisfactory. Conclusions: The applicability of the new concept of Spasticity-Plus in MS clinical practice seems possible and may lead to an integrated management of several MS symptoms, thus reducing the treatment burden of disease symptoms. The study was funded by an investigational grant from Almirall SA 2025-10-24T07:46:58Z 2025-10-24T07:46:58Z 2023-03-21T11:04:42Z 2023-03-21T11:04:42Z 2021-09-27 info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion http://hdl.handle.net/11351/9215 Frontiers in Neurology;12 https://doi.org/10.3389/fneur.2021.722801 Attribution 4.0 International http://creativecommons.org/licenses/by/4.0/ info:eu-repo/semantics/openAccess Frontiers Media Scientia